OnCo

RNF213 (E3 ubiquitin-protein ligase RNF213) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Atypical E3 ubiquitin ligase that can catalyse ubiquitination of both proteins and lipids, and which is involved in various processes, such as lipid metabolism, angiogenesis and cell-autonomous immunity. Acts as a key immune sensor by catalysing ubiquitination of the lipid A moiety of bacterial lipopolysaccharide (LPS) via its RZ-type zinc-finger: restricts the proliferation of cytosolic bacteria, such as Salmonella, by generating the bacterial ubiquitin coat through the ubiquitination of LPS. Also acts indirectly by mediating the recruitment of the LUBAC complex, which conjugates linear polyubiquitin chains. Ubiquitination of LPS triggers cell-autonomous immunity, such as antibacterial autophagy, leading to degradation of the microbial invader. Also functions as an intracellular sensor for ISGylated proteins: upon type I interferon stimulation, undergoes ISGylation and oligomerises on lipid droplets to form a binding platform for ISG15-modified substrate proteins, thereby acting as a broad-spectrum antimicrobial effector. Restricts intracellular bacterial pathogens, such as Listeria monocytogenes, in an ISG15-dependent manner by decorating the bacterial surface with ubiquitin to promote autophagic clearance. Location: Cytoplasm, cytosol; Lipid droplet (UniProt). Locus 17q25.3 (HGNC).

Where it is found
  • Prostate cancer: IntOGen driver in 2 cohorts (PRAD)
  • Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
  • Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
  • Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
  • Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
  • Angiosarcoma: IntOGen driver in 1 cohort (ANGS)
Class: enzyme · Gene: RNF213 · Facts checked 2026-09-23 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"RNF213" OR ABSTRACT:"RNF213" OR TITLE:"ring finger protein 213" OR ABSTRACT:"ring finger protein 213" OR TITLE:"E3 ubiquitin-protein ligase RNF213" OR ABSTRACT:"E3 ubiquitin-protein ligase RNF213" OR TITLE:"KIAA1554" OR ABSTRACT:"KIAA1554" OR TITLE:"NET57" OR ABSTRACT:"NET57" OR TITLE:"ALO17" OR ABSTRACT:"ALO17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RNF213, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rnf213.json. Licence CC BY-NC 4.0.